<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To report 4 cases of refractory <z:hpo ids='HP_0012121'>panuveitis</z:hpo> due to <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease treated with a novel therapy: infliximab </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Retrospective study of 3 women and 1 man of Causasian origin with <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease complicated with <z:hpo ids='HP_0012121'>panuveitis</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Their <z:hpo ids='HP_0000554'>uveitis</z:hpo> was relapsing from 48 to 96 months and was resistant to the combination of <z:chebi fb="0" ids="23359">colchicine</z:chebi> (n = 4), high-dose <z:chebi fb="0" ids="8382">prednisone</z:chebi> (n = 4), pentoxyphilline (n = 2) and various immunossuppressors and/or immunomodulators given successively: intravenous <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (n = 4), <z:chebi fb="2" ids="2948">azathioprine</z:chebi> (n = 3), interferon alpha (n = 3), <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> A (n = 2), oral <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (n = 1), <z:chebi fb="0" ids="168396">mycophenolate</z:chebi> mofetil (n = 1), <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (n = 1), high-dose immunoglobulin (n = 1) </plain></SENT>
<SENT sid="3" pm="."><plain>Combination with respectively 1, 3, 4 and 5 immunossuppressors and/or immunomodulators failed before institution of infliximab </plain></SENT>
<SENT sid="4" pm="."><plain>After informed consent was obtained, infliximab was administered as a single infusion of 5 mg/kg (maximum dose: 400 mg) at day 1, at week 2, 6 and then every 8 weeks </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: With a follow-up ranging from 7 to 22 months, infliximab was efficient in <z:hpo ids='HP_0000001'>all</z:hpo> cases </plain></SENT>
<SENT sid="6" pm="."><plain>The mean <z:chebi fb="0" ids="8382">prednisone</z:chebi> dose decreased from 45 mg to 13 mg daily </plain></SENT>
<SENT sid="7" pm="."><plain>Total recovery of visual acuity was observed in half of the cases </plain></SENT>
<SENT sid="8" pm="."><plain>Infliximab was well tolerated without <z:hpo ids='HP_0001945'>fever</z:hpo>, severe <z:hpo ids='HP_0100806'>sepsis</z:hpo> or autoimmune manifestation </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: Infliximab may be efficient in refractory <z:hpo ids='HP_0000554'>uveitis</z:hpo> due to <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease </plain></SENT>
<SENT sid="10" pm="."><plain>The optimal dose, rhythm and duration of infliximab infusions need to be standardized </plain></SENT>
</text></document>